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Abstract
Objective: To investigate the role of IL-17RA signaling in the effector phase of inflammatory arthritis using the K/BxN serum-
transfer model.
Methods: Wild-type and Il17ra
2/2 mice were injected with serum isolated from arthritic K/BxN mice and their clinical score
was recorded daily. Mice were also harvested on days 12 and 21 and ankles were analyzed for cytokine and chemokine
mRNA expression by qPCR on day 12 and for bone and cartilage erosions by histology on day 21, respectively. The induction
of cytokine and chemokine expression levels by IL-17A in synovial-like fibroblasts was also analyzed using qPCR.
Results: Il17ra
2/2 mice were partially protected from clinical signs of arthritis and had markedly fewer cartilage and bone
erosions. The expression of several pro-inflammatory mediators, including the chemokines KC/CXCL1, MIP-2/CXCL2, LIX/
CXCL5 MIP-1c/CCL9, MCP-3/CCL7, MIP-3a/CCL20, the cytokines IL-1b, IL-6, RANKL and the matrix metalloproteinases MMP2,
MMP3, and MMP13 were decreased in the ankles of Il17ra
2/2 mice compared to wild-type mice. Many of these
proinflammatory genes attenuated in the ankles of Il17ra
2/2 mice were shown to be directly induced by IL-17A in synovial
fibroblasts in vitro.
Conclusions: IL-17RA signaling plays a role as an amplifier of the effector phase of inflammatory arthritis. This effect is likely
mediated by direct activation of synovial fibroblasts by IL-17RA to produce multiple inflammatory mediators, including
chemokines active on neutrophils. Therefore, interrupting IL-17RA signaling maybe a promising pharmacological target for
the treatment of inflammatory arthritis.
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Introduction
The IL-17 cytokine family has been implicated in the
pathogenesis of numerous autoimmune diseases, including rheu-
matoid arthritis [1]. IL-17A and IL-17F are the most homologous
(55%) members of this family and exhibit overlapping functions
[2]. Both cytokines bind to the same IL-17 receptor complex
consisting of the receptor subunits IL-17RA and IL-17RC [3,4].
IL-17A and IL-17F are both expressed in the joints of RA patients
[5–10]. Likewise, the expression of their receptor subunits, IL-
17RA and IL-17RC, is enhanced in the blood and synovium of
RA patients [11]. Therefore, IL-17A and IL-17F may both
participate in the pathogenesis of rheumatoid arthritis.
IL-17A has been implicated in arthritogenesis in several mouse
models of RA [12–16]. Notably, the relative importance of IL-17A
in these models differs: the more T cell-dependent the model, the
more pivotal the role of IL-17RA signaling [17]. This suggests that
IL-17A is particularly involved in the initiation phase of arthritis,
generally characterized by the generation of an autoimmune
response. For example, in the spontaneous K/BxN mouse model,
IL-17A was required for the generation of anti-GPI autoantibodies
[18].
In the K/BxN serum transfer model of inflammatory arthritis,
the initiation phase of arthritis is bypassed by passive transfer of
anti-GPI-containing K/BxN serum into recipient mice, which
induces acute arthritis. Thus, the K/BxN serum transfer model
allows studies to focus specifically on the effector phase of
inflammatory arthritis, which is primarily driven by innate
immune cells [19,20]. While T cells are generally not required
for the induction of acute arthritis in this serum transfer model, it
has recently been shown that arthritis in B cell-deficient BxN mice
is reinforced by adoptive transfer of KRN T cells [21]. This
reinforcement depended on the release of IL-17A [21]. The
molecular mechanism of this reinforcement, however, was not
addressed, nor was the involvement of IL-17RA signaling in the
K/BxN serum transfer model.
In human RA, the synovial fluid of inflamed joints is largely
infiltrated by neutrophils. Likewise, neutrophils dominate the
synovial fluid infiltrate in inflamed joints in both the spontaneous
K/BxN model and the K/BxN serum transfer model, and
neutrophils have been shown to be indispensable for the
generation of serum-induced arthritis [20,22]. IL-17A and IL-
17F have been shown to promote the infiltration of neutrophils
into inflammatory sites [23] and to induce the expression of
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fibroblast-like synoviocytes (FLS) [9,11].
In this study, we addressed the role of IL-17RA signaling in the
effector phase of arthritis using the K/BxN serum transfer model
and show that IL-17RA signaling reinforces destructive arthritis.
We found that IL-17RA contributes to the effector phase of
arthritis through the direct induction of neutrophil-active chemo-




2/2 mice on the C57BL/6 back-
ground [23] were kindly provided by Amgen (Seattle, WA) and bred
under specific pathogen free conditions, which included Helicobac-
ter pylori and Pasteurella pneumotropica (HPP), at the Massachu-
setts General Hospital. HPP-free wild-type C57BL/6 mice were
purchased from The Jackson Laboratory (Bar Harbor, ME). KRN
mice were kindly provided by Diane Mathis and Christophe Benoist
(HarvardMedicalSchool,Boston,MA).K/BxNmicewereobtained
by crossing KRN with NOD/LtJ mice (The Jackson Laboratory,
Bar Harbor, ME) in our animal facility. All experiments were
performed according to protocols approved by the Massachusetts
General Hospital Subcommittee on Research Animal Care. Age-
and sex-matched, 6–12 week old mice were used in all experiments.
Serum transfer and clinical evaluation
K/BxN serum was harvested from 8-week-old arthritic K/BxN
mice, pooled and stored at 280uC until usage. For induction of
arthritis 150 ml of serum was injected i.p. into recipient mice on days
0 and 2 of the experiment. The clinical score for each paw was
evaluated at least every second day based on the following index: 0,
no edema/erythema; 1, localized edema/erythema over one surface
of the paw; 2, edema/erythema involving the entirety of one surface
of the paw; 3, edema/erythema involving both surfaces of the paw.
Scores were added for all four paws to obtain a composite score with
a maximum of 12. Ankle thickness was determined with a pocket
thickness gage (Mitutoyo USA, Aurora, IL) and ankle thickening
(ankle swelling compared to baseline on day 0) was calculated as the
mean difference between the current ankle thickness and the ankle
thickness of each hindpaw on day 0 before serum injection.
Histopathology
Mice were sacrificed on day 7 and day 21. Ankles were dissected
and fixed in 4% neutral buffered paraformaldehyde, demineral-
ized in modified Kristensen’s solution, and stained with toluidine
blue. Inflammation, cartilage and bone erosions were scored as
described with 0, normal; 1, minimal; 2, mild; 3, moderate; 4,
marked; 5, severe [24].
Determination of the number of neutrophils in the
synovial fluid
Ankles were dissectedon day12 afterserum transfer and lavaged.
The infiltrates from both ankles of an individual mouse were
combined and stained with anti-Ly6G FITC (R&D Systems,
Minneapolis, MN). Afterwards, counting beads (Invitrogen, Carls-
bad, CA) were added according to manufacturer’s instructions and
the number of Ly-6G
+ cells was determined by FACS analysis.
RNA isolation and qPCR
Total RNA was isolated using TRIzol (Invitrogen, Carlsbad,
CA) and treated with DNase I (Invitrogen, Carlsbad, CA)
according to the manufacturers’ instructions. The total RNA
concentration was determined with a Nanodrop (ThermoFisher
Scientific, Waltham, MA) and total RNA was reverse transcribed
using oligo(dT), random hexamers, and multiscribe reverse
transcriptase (Applied Biosystems, Foster City, CA). QPCR was
performed using 1 ml cDNA per well, SYBR green master mix
(Applied Biosystems, Foster City, CA), and sense and antisense
primers 250 nmol each. All primers for qPCR were purchased
from Integrated DNA Technologies (Coralville, IA) and primer
sequences are listed in Table S1. QPCR was conducted with the
MX4000 qPCR machine (Stratagene). Data were analyzed using
MX4000 software version 3.0 (Stratagene). Results were evaluated
using the DDCT method and the calculated number of copies was
normalized to the number of b2 microglobulin mRNA copies in
the same sample.
Comparison of mRNA expression in the ankle joints of
wild-type and Il17ra
2/2 mice after serum-transfer
Arthritis was induced in WT and Il17ra
2/2, as described above.
On day 12, for the generation of whole joint lysates, joints were
dissected, immediately put into TRIzol and minced using a
polytron at 4uC. Total RNA was isolated and DNase I treated, as
described above. For reverse transcription, 1 mg of total RNA was
used.
Isolation of murine bone marrow-derived neutrophils
and synovial-like fibroblasts (FLS)
Bone marrow-derived neutrophils used for in vitro experiments
were isolated using an immunomagnetic separation strategy.
Freshly harvested mouse bone marrow leukocytes were first
stained with PE-conjugated anti-Ly6G (BD Biosciences, San Jose,
CA) and then isolated using EasySepH PE selection kits (Stem Cell
Technologies, Vancouver, Canada) and immediately used for
experiments. Synovial-like fibroblasts (FLS) were obtained from
C57Bl/6 mouse ankle tissues. Dissected ankle tissues were
infiltrated and digested in Type IV collagenase (Worthington
Corporation, Lakewood, NJ). After an overnight culture in tissue
culture flasks, non-adherent cells were washed away and adherent
cells were maintained in DMEM supplemented with 10% heat-
inactivated FCS, 2 mM glutamine, 100 U/ml penicillin, 100 mg/
ml streptomycin, and 50 mM 2-mercaptoethanol. Fibroblast
monolayers were cultured until confluent and used between the
fourth and eighth passages.
Stimulation of FLS with IL-17A
150,000 FLS per well were seeded into 12-well plates (Corning,
Lowell, MA). After 2 days, cells were washed and 1.5 ml fresh
medium was added. Cells were either left untreated or stimulated
with 100 ng/ml IL-17A (R&D Systems, Minneapolis, MN). After
16 h, total RNA was harvested and 0.5 mg RNA were used for
reverse transcription.
Chemotaxis assays
Chemotaxis of neutrophils was assessed in vitro using both 24-
well transwell plates (Corning; Lowell, MA) and the ChemoTxH
System (Neuro Probe, Gaithersburg, MD). Freshly prepared bone
marrow neutrophils were suspended in RPMI containing 2 nM
glutamine, 25 nM HEPES and 1% fatty-acid free BSA at a
concentration of 5610
6 cells/ml and chemotaxis was assessed to
varying concentrations of IL-17A (R&D Systems, Minneapolis,
MN). 100 nM leukotriene B4 (Cayman Chemical, Ann Arbor, MI)
or 100 nM recombinant murine MIP-2 (R&D Systems) served as
positive controls. Chemotaxis was quantified after incubation for
1 h at 37uC, 5% CO2.
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neutrophil suspension was seeded into the insert of a 24-well co-
culture plate with a pore size of 5 mm. Migrated cells were
harvested from the lower well, spun down and resuspended in
PBS. Counting beads (Invitrogen, Carlsbad, CA) were added
according to manufacturer’s instructions and the absolute number
of neutrophils in each sample was assessed by FACS analysis. For
assays using the ChemoTxH System, chemoattractants were
placed in the bottom chamber of a 96-well ChemoTx disposable
plate and neutrophils were seeded on the top of a 3 mm pore size
membrane. For chemokinesis controls, chemoattractants were
added to the cells on top instead of into the bottom chamber.
Neutrophils that migrated into the lower chamber after 1 h of
incubation at 37uC, 5% CO2 were counted with an inverted
microscope and the chemotactic index (CI) was calculated by
establishing the ratio between the number of cells that migrated in
the presence of a chemoattractant to the number of cells that
migrated in complete absence of a chemoattractant (medium
control).
Statistics
All data are presented as mean 6 SEM. Raw data were
analyzed by unpaired two-tailed Student’s t test or Mann-
Whitney-Wilcoxon test, as indicated. In case of more than two
groups, data were analyzed by One-way-ANOVA with Bonferroni
posttest. A value of p,0.05 was considered statistically significant.
To test for statistical differences between the wild-type and
Il17ra
2/2 mice in ankle thickness and clinical score, the area
under curve (AUC) for every individual mouse in each group was
calculated and their means were compared. All calculations were
performed with GraphPad Prism 4.0 software.
Results
Serum-induced arthritis is attenuated in Il17ra
2/2 mice
To determine the role of IL-17RA signaling in the effector
phase of inflammatory arthritis, we analyzed the development of
arthritis in Il17ra
2/2 mice compared to wild-type mice following
the transfer of arthritogenic K/BxN serum transfer. Clinical signs
of arthritis developed in both groups of mice with a similar time
course. However, the clinical signs of arthritis were attenuated in
Il17ra
2/2 mice compared to wild-type mice throughout the entire
course of the disease (Fig. 1A). The difference was more
pronounced in ankle thickness than in the clinical score.
Il17ra
2/2 mice showed approximately 40% less ankle thickness
than wild-type mice at the peak of ankle thickening on day 10
(Fig. 1A). Calculating the area under the curve (AUC) for both
ankle thickness and the clinical score for every individual mouse
and comparing the means of the WT and the Il17ra
2/2 groups
showed a statistically significant difference for both parameters.
The comparison of the AUCs of three independent experiments
was different in both clinical scoring and ankle thickness with a
reduction of approximately 42% and 58% for the clinical score
and the ankle thickening, respectively (Fig. 1B). Comparison of the
peak clinical score and the peak ankle thickness of the individual
mice of the same three experiments showed a decrease in peak
ankle thickness in Il17ra
2/2 mice as well (Fig. 1C). There was a
trend towards a lower peak clinical score in Il17ra
2/2 mice,
although it did not reach statistical significance. Histopathological
scoring for cartilage and bone erosions in wild-type and Il17ra
2/2
mice 21 days after serum transfer revealed that Il17ra
2/2 mice
had markedly reduced cartilage and bone erosions compared to
wild-type mice (Fig. 1D). Histological evidence of inflammation
was not different between these groups of mice and by 21 day
evidence of inflammatory cell infiltration had almost completely
resolved in both groups (data not shown).
Reduced numbers of neutrophils in the joints of Il17ra
2/2
mice
Since the synovial infiltrate in serum-induced arthritis is largely
neutrophils, we determined the number of neutrophils found in
the synovial fluid on day 12 after serum transfer. Day 12 was
chosen because the difference in arthritis between the WT and the
Il17ra
2/2 group was most pronounced at this time point. To
determine the number of neutrophils present in the synovial fluid
of the ankle, leukocytes recovered from joints by lavage were
stained for Ly6G
+ cells to identify neutrophils. The number of
neutrophils in the sample was determined using FACS analysis in
the presence of counting beads. The synovial fluid of Il17ra
2/2
mice was infiltrated by fewer neutrophils than the synovial fluid of
wild-type mice (Fig. 2A).
There are conflicting data in the literature concerning the direct
responsiveness of neutrophils to IL-17A [25,26]. Therefore, we
investigated the direct effect of IL-17A on neutrophils. Stimulation
of neutrophils with IL-17A (100 ng/ml) for 3 h, 16 h or 24 h had
no effect on gene expression of IL-6, numerous chemokines,
RANKL, MMP2, MMP3, MMP13, IL-1b or TNF-a (data not
shown). We also tested if varying concentrations of IL-17A could
induce migration of freshly isolated murine bone marrow
neutrophils in chemotaxis assays (Fig. 2B). While LTB4 and
MIP-2 induced significant neutrophil migration and served as
positive controls, IL-17A failed to induce neutrophil chemotaxis.
Therefore, it is unlikely that IL-17A directly induces significant
neutrophil recruitment in vivo. This assumption was further
supported by the fact that murine neutrophils do not express IL-
17RC mRNA, although they do express IL-17RA mRNA
(Fig. 2C). Combined expression of IL-17RA and IL-17RC is a
prerequisite for a functional IL-17 receptor complex in both mice
and humans [26–28].
The induction of pro-inflammatory mediators in the joint
is attenuated in Il17ra
2/2 mice
On day 12 following arthritogenic serum transfer, joints of wild-
type and Il17ra
2/2 mice were harvested and total RNA, isolated
from whole ankle joint lysates, was used for gene expression
analysis by qPCR. Compared to wild-type mice, several genes
were markedly attenuated in the ankles of Il17ra
2/2 mice
(Table 1). The expression of the pro-inflammatory cytokines IL-
1b and IL-6 was significantly lower. IL-1b expression in the joint
has previously been shown to be essential for the development of
serum-induced arthritis with neutrophils as a major source for this
cytokine [29,30]. We have recently shown that CCR1 and
CXCR2 are needed for the development of full-blown serum-
induced arthritis. Consistent with these previous data, Il17ra
2/2
mice had diminished expression of the CXCR2 ligands KC/
CXCL1, MIP-2/CXCL2, and LIX/CXCL5, and the CCR1
ligands MIP-1a/CCL3, MIP-1c/CCL9, and MCP-3/CCL7
(Table 1).
MIP-3a/CCL20 is the only known chemokine ligand for
CCR6, a chemokine receptor expressed on Th17 and cd T cells.
Both cell types are potential sources for IL-17A and IL-17F. We
found MIP-3a/CCL20 mRNA expression was enhanced in the
inflamed joints and that IL-17RA deficiency blunted the
expression of this chemokine in the joint (Table 1). Recently, IL-
33 has been linked to arthritis and the recruitment of neutrophils
into the joint. Synovial cells are considered as the major source for
IL-33 in arthritis [31–33]. Significant levels of IL-33 mRNA were
IL-17RA in the Effector Phase of Inflammation
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levels tended to be decreased in the joints of Il17ra
2/2 mice
compared to wild-type mice (Table 1), suggesting a possible link
between those two amplifiers of arthritis. Expression of IL-17A has
also been linked to bone and cartilage erosions through the
induction of RANKL, which is induced in inflamed joints
Figure 1. IL-17RA deficiency attenuates severity of K/BxN serum induced arthritis. A, WT (n=9) and Il17ra
2/2 mice (n=10) were injected
with K/BxN serum and were monitored for 20 days recording daily ankle thickness and clinical score. Data are presented as mean 6 SEM. The AUC for
the ankle thickness and for the clinical score of every individual mouse was calculated and statistical differences between wild-type and Il17ra
2/2
mice were determined by unpaired two-tailed Student’s t test. One representative of three independent experiments is shown. The number of mice
stated above refers to this one representative experiment. B, AUCs for the ankle thickness and the clinical score of WT (n=17) and Il17ra
2/2 mice
(n=18) were calculated. Each column represents mean 6 SEM. Data were pooled from three independent experiments, and statistical differences
were determined by unpaired two-tailed Student’s t test. C, Peak ankle thickness and the peak clinical score reached by each WT (N) (n=17) and
Il17ra
2/2 (m) mice (n=18) are shown. Each dot or triangle represents one individual mouse. Data were pooled from three independently performed
experiments. D, Histopathological score of cartilage and bone erosions in WT (n=9) and Il17ra
2/2 mice (n=10) are presented as mean 6 SEM from
ankles harvested on day 21. Data shown are from one representative out of three independently performed experiments. Histopathological score was
assessed in toluidine-blue stained specimens. Representative histologies for the wild-type and Il17ra
2/2 groups are shown. The asterisk marks a site
of pannus infiltration into the bone already visible under low magnification. The arrow indicates a site of proteoglycan loss of the cartilage. Both
findings were typical for the wild-type group but not for the Il17ra
2/2 group. In (C) and (D) statistical analyses were conducted using Mann-Whitney-
Wilcoxon test. *=p,0.05; **=p,0.01; ***=p,0.001.
doi:10.1371/journal.pone.0026342.g001
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was inhibited in the absence of IL-17RA signaling (Table 1).
Likewise, Il17ra
2/2 mice had reduced mRNA levels of the matrix
metalloproteinases MMP2, MMP3, and MMP13 (Table 1). There
was also a trend towards lower VEGF-A levels in the joints of
Il17ra
2/2 mice following serum transfer (Table 1). VEGF-A is a
critical mediator of angiogenesis and has previously been linked to
arthritis development K/BxN mice [34].
IL-17A induces neutrophil-active chemokines and MMPs
in FLS in vitro
Synovial cells play a crucial active role in the development of
RA, and IL-17A has previously been shown to directly activate
synovial cells in vitro [11,13]. In order to determine which of the
genes downregulated in the ankles of Il17ra
2/2 mice might be
directly regulated by IL-17RA signaling, murine fibroblast-like
synoviocytes (FLS) were either left unstimulated or stimulated with
100 ng/ml IL-17A for 16 h. RNA was then isolated and gene
expression assessed by qPCR. IL-17RA signaling in FLS induced a
number of genes, which were down-regulated in the joints of
Il17ra
2/2 mice, suggesting that IL-17A directly regulated these
genes in vivo. In particular, the expression of the neutrophil-active
CXCR2 chemokines ligands KC/CXCL1 and LIX/CXCL5 was
strongly induced by IL-17A in FLS. The neutrophil active CCR1
ligand CCL9/MIP-1c was also induced but to a lesser extent. In
addition, the expression of IL-6, MCP-3/CCL7 and the CCR6
ligand MIP-3a/CCL20 and was also induced by IL-17A in FLS
(Table 2). Of note, the induction of the CCR6 ligand CCL20 by
IL-17A in FLS may serve as a positive feedback loop to reinforce
IL-17-driven inflammation by recruiting IL-17 producing CCR6-
Figure 2. Neutrophils are reduced in the joints of Il17ra
2/2 mice
and are unresponsive to direct stimulation with IL-17A. A,
Number of neutrophils in the ankle joints of WT and Il17ra
2/2 mice on
day 12 was determined by FACS analysis counting Ly6G
+ cells in
relation to counting beads. Data are presented as mean 6 SEM (n=3
mice per group). One of three independent experiments is shown. B,
Chemotaxis of freshly isolated murine bone marrow-derived neutro-
phils towards 100 nM LTB4 and IL-17A (10 and 100 ng/ml) assessed
using 24-well transwell assays. Data represent numbers of migrated
neutrophils (n=3 independently performed experiments). C, Chemo-
taxis of freshly isolated murine bone marrow-derived neutrophils
towards LTB4 (100 nM) MIP-2 (100 nM) and IL-17A (1, 10, 100, 1000 ng/
ml) as well as their corresponding chemokinesis controls assessed using
96-well ChemoTx assays. Data are presented as chemotactic index
(number of cells migrating to chemoattractant/number of cell
migrating to medium control). Data shown are mean 6 SEM (n=4
independently performed experiments). D, Levels of IL-17RA and IL-
17RC mRNA determined by qPCR on RNA isolated from murine FLS and
freshly isolated bone marrow-derived neutrophils (n=3 independently
performed experiments). Data were compared by unpaired two-tailed
Student’s t test, **=p,0.01 compared to wild-type control (A), or by
One-way-ANOVA with Bonferroni posttest, **=p,0.01 compared to
medium control (B) or ***=p,0.001 LTB4 and MIP-2 each individually
compared to all other groups (C).
doi:10.1371/journal.pone.0026342.g002






IL-1b 4.7±0.67 1.2±0.39 0.0001
IL-6 2.561.2 0.260.08 0.0599
KC/CXCL1 2.8±0.8 0.5±0.3 0.0136
MIP-2/CXCL2 5.5±1.1 1.7±0.7 0.0104
LIX/CXCL5 9.2±1.6 2.6±1.0 0.0017
MIP-1c/CCL9 1.5±0.3 0.7±0.3 0.0213
MIP-3a/CCL20 0.2±0.04 0.06±0.02 0.0018
MIP-1a/CCL3 0.560. 1 0.260.06 0.0533
RANTES/CCL5 3.461.2 4.562.1 0.6589
MCP-3/CCL7 9.0±1.7 2.3±0.7 0.0014
MIP-3b/CCL19 1.060.2 0.960.2 0.6408
RANKL 0.8±0.2 0.3±0.1 0.0435
IL-33 1.960.6 0.960.6 0.1343
VEGF-A 1.860.4 1.060.2 0.0536
MMP2 45.1±9.4 18.2±7.8 0.0379
MMP3 22.5±4.7 7.1±2.9 0.0106
MMP13 11.663.1 4.761.5 0.0562
RNA expression in the ankles of wild-type and Il17ra
2/2 mice after serum-
transfer. WT and Il17ra
2/2 mice were injected with K/BxN serum. On day 12,
total RNA was harvested from whole ankle lysates and RNA levels assessed by
qPCR. Data were normalized to the number of b2 microglobulin mRNA copies.
Results are presented as the 100-fold of the mean of mRNA copies/b2
microglobulin mRNA copies 6 SEM (n=13 mice per group). Data are compiled
from three independent experiments. Differences were evaluated by unpaired
two-tailed Student’s t test; p,0.05 was considered statistically significant and is
indicated in bold.
doi:10.1371/journal.pone.0026342.t001
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in the synovium of RA patients [35], however, a possible role of
MIP-3a/CCL20 in serum-induced arthritis has never been
addressed.
Importantly, IL-17A also markedly induced the expression of
genes linked to cartilage and bone erosions, such as RANKL and
the matrix metalloproteinases MMP3 (Table 2) [24]. Stimulation
with IL-17A did not affect the expression of VEGF-A, MIP-1a/
CCL3, or MMP2, while MIP-2/CXCL2, IL-33 and MMP13
appeared to be minimally induced (,2-fold) (Table 2). IL-1b
mRNA expression was undetectable in FLS.
Discussion
In this study, we addressed the contribution of IL-17RA
signaling to the effector phase of arthritis in the K/BxN serum
transfer model by subjecting Il17ra
2/2 mice to serum transfer and
found that IL-17RA deficiency attenuated the severity of serum-
induced arthritis. Clinical signs of arthritis, cartilage and bone
erosions, and the expression of chemokines and MMPs in the
joints were all reduced. Thus, IL-17RA signaling appears to be
involved in the effector phase of serum-induced arthritis. IL-17RA
deficiency, however, did not completely abrogate arthritis. Instead,
the presence of other pro-inflammatory cytokines, such as IL-1b,
was sufficient to generate arthritis, leaving IL-17RA signaling as an
amplifier of serum-induced arthritis rather than an absolutely
required mediator. The notion that IL-17RA amplifies of arthritis
is further supported by the observation that overexpression of IL-
17A aggravates serum-induced arthritis [36].
In Il17ra
2/2 mice, the biological activity of both IL-17A and
IL-17F is completely abrogated, so residual disease in Il17ra
2/2
mice is mediated by cytokines other than IL-17A or IL17F. The
overlapping roles of IL-17A and IL-17F may explain why Jacobs
et al. [21] did not detect a decrease in ankle thickening in serum-
induced arthritis in C57BL/6 mice treated with an antibody to just
IL-17A. Another explanation for these discrepant results may be
that we observed that the attenuation of arthritis in Il17ra
2/2 mice
was most pronounced from day 10 through day 20, after arthritis
had already reached its peak in both groups. Jacobs et al. injected
anti-IL-17A antibody on days 0, 2, and 4. Conceivably, on days 10
to 20, the anti-IL-17A antibody concentration was already too low
to inhibit IL-17A sufficiently.
Although Th17 cells are the most prominent source of IL-17A
and IL-17F, they are not the only source for the two cytokines.
Instead, a broad array of cells of the innate and adaptive immune
system, including cd T cells, CD8
+ T cells, natural killer (NK) and
natural killer T (NKT) cells, monocytes and neutrophils, are
capable of producing these two cytokines [28,37]. For instance, in
collagen-induced arthritis, cd T cells have been shown to be the
major source of IL-17A in the inflamed joint [38]. The induction
of IL-17A in cd T cells was not dependent on engagement of the T
cell receptor but on activation of the cd T cells by IL-1b and IL-23
[38]. Most intriguingly, a recent study identified tissue mast cells as
the major source for IL-17A in RA patients [39]. The release of
IL-17A from mast cells could be induced by stimulation with
immune complexes or C5a [39]. Since mast cells are believed to
participate in the induction of serum-induced arthritis via
activation of their Fcc receptors and the C5aR [40,41], it is
tempting to speculate that they are also an important source of IL-
17 family cytokines in this mouse model.
We have recently shown that CCR1 and CXCR2 play crucial
non-redundant roles in serum-induced arthritis and together
account for all of the neutrophil chemokine activity in the model
[30]. While deficiency in CCR1 delayed the initiation of arthritis
and slightly attenuated its maximal expression, Cxcr2
2/2 mice
exhibited a nearly indistinguishable early phase of arthritis
compared to wild-type mice but in later stages showed a marked
attenuation of neutrophil recruitment into the joint and disease. In
the joints of Il17ra
2/2 mice, mRNA levels of CCR1 and CXCR2
ligands were markedly diminished with attenuation of CXCR2
ligands being more pronounced. Accordingly, although arthritis in
Il17ra
2/2 mice was attenuated in all phases, the more pronounced
clinical difference was found in the second phase of arthritis when
the arthritis is amplified and maintained by CXCR2 chemokine
ligands. In addition, IL-17A potently induced these CXCR2
chemokine ligand mRNA in FLS in vitro, suggesting a direct
mechanism of neutrophil active chemokine induction by IL-17A in
synovial cells in vivo. Their lower expression in the inflamed joints
of Il17ra
2/2 mice therefore could explain the diminished number
of neutrophils found in the synovial fluid of Il17ra
2/2 mice
compared to wild-type mice. It should be noted that chemokine
mRNA levels and not proteins levels were analyzed so caution
should been used when interpreting these data. Nevertheless, these
data suggest that the local induction of CXCR2 and CCR1
chemokines in the synovium is likely the major mechanism of the
amplification of serum-induced arthritis by IL-17RA signaling.
Consistent with this, it has been shown that the acute infiltration of
the joint by neutrophils after an intraarticular re-challenge with
methylated bovine serum albumin (mBSA) depends on the local
production of IL-17A and the subsequent downstream release of
LTB4, CXCL1, CXCL5, and TNF-a [27]. In this study, however,
a direct effect of IL-17A on neutrophils was proposed with IL-17A
exerting a chemotactic effect on neutrophils in vitro dependent on
Table 2. Gene expression in FLS after stimulation with IL-17A.
mRNA copies/b2 microglobulin6100
Control IL-17A p-value
IL-1b n.d. n.d. -
IL-6 0.065±0.01 2.1±0.3 0.003
KC/CXCL1 6.4±0.6 80.4±18.1 0.015
MIP-2/CXCL2 0.1460.03 0.3360.09 0.102
LIX/CXCL5 27.8±1.7 641.9±123.5 0.008
MIP-1c/CCL9 1.1±0.1 2.0±0.2 0.015
MIP-3a/CCL20 0.02±0.004 0.74±0.16 0.011
MIP-1a/CCL3 0.1760.02 0.1460.03 0.360
MIP-3b/CCL19 0.4460.05 0. 8060.13 0.059
MCP-3/CCL7 40.7±4.4 252.4±49.5 0.013
RANTES/CCL5 0. 3260.086 0.6060.09 0.091
RANKL 1.37±0.05 7.4±1.1 0.006
IL-33 1.960.14 3.1560.48 0.068
VEGF-A 20.561.4 24.065.3 0.553
MMP2 277.3638.4 271.6641.4 0.924
MMP3 115.3±16.9 339.5±45.0 0.010
MMP13 103.363.3 249.2671.3 0.110
Genes induced in FLS by IL-17A. FLS were left unstimulated or stimulated with
100 ng/ml IL-17A. After 16 h, total RNA was harvested and gene expression was
determined by qPCR. Data shown represent the 100-fold of the mean of mRNA
copies/b2 microglobulin mRNA copies 6 SEM (n=3 independent experiments).
Differences were evaluated by unpaired two-tailed Student’s t test; p,0.05 was
considered statistically significant and is indicated in bold.
doi:10.1371/journal.pone.0026342.t002
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were not responsive to direct stimulation with IL-17A. IL-17A did
not induce neutrophil chemotaxis or alter gene expression profiles
in vitro. Recent literature on the direct responsiveness of
neutrophils to IL-17A is conflicting. Other investigators have
reported that IL-17A is unable to directly stimulate human
neutrophils [26]. Deficiency of IL-17RA signaling resulted in a
marked reduction in cartilage and bone erosions. The develop-
ment of cartilage and bone erosions in serum-induced arthritis is
critically dependent on RANKL [24]. Consistent with this,
RANKL mRNA expression was strongly reduced in the joints of
Il17ra
2/2 mice. Furthermore, IL-17A directly induced RANKL in
FLS in vitro, suggesting IL-17RA signaling directly contributes to
cartilage and bone erosion via induction of RANKL. MMPs are
considered to participate in the development of arthritis, not only
by remodeling the joint structure, but also by proteolytically
activating chemokines and cytokines thus amplifying inflammation
[42,43]. Accordingly, we detected enhanced mRNA levels of
MMP2, MMP3, and MMP13 in the ankle joints and a
considerable decrease in the absence of IL-17RA signaling. In
regard to our in vitro experiments, MMP3 and MMP13 may also
be directly induced by IL-17A in FLS. Although these data suggest
activation of these MMPs by IL-17A both in vivo and in vitro,i ti s
important to note that regulation of MMP activity additionally
occurs at the posttranslational level, which may be independent of
IL-17RA signaling.
The tumor-like proliferation of FLS and their infiltration into
cartilage and bone are a major cause of cartilage and bone
erosions in RA. Recently, it has been shown that IL-17RA
signaling exerts anti-apoptotic effects in vivo, promoting synovial
hyperplasia and thus may contribute to the chronicity of RA [44].
We have not addressed possible anti-apoptotic effects of IL-17RA
signaling on FLS in our model. The more pronounced difference
in cartilage and bone erosions between the wild-type and the
Il17ra
2/2 group compared to the relatively small difference in
clinical signs, particularly in the first 10 days of arthritis, however,
suggests that the marked protection of Il17ra
2/2 mice from bone
and cartilage erosions may be the result of a dual effect of reduced
inflammatory mediator production and anti-proliferative effects
from lack of IL-17RA signaling.
The K/BxN serum transfer model most closely resembles an
acute clinical flare in patients with established RA. Our results
suggest that IL-17RA signaling may amplify and sustain arthritis
in this clinical situation. Recently, IL-17A has been implicated in
sustaining established rheumatoid arthritis [10]. Prior human
studies had suggested that the involvement of IL-17A in the
pathogenesis of rheumatoid arthritis was limited to its initial phase
characterized by the development of an autoimmune response.
Our data now lend support to the notion that IL-17RA signaling
may play a contributory role in multiple phases of human RA and
thus should be considered as a promising pharmacological target
for established arthritis. Our data, however, also suggest that
inhibition of IL-17RA signaling is unlikely to induce complete
remission when used as monotherapy and should be considered as
adjunctive therapy.
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